(LYM7) Multi Units France - Lyxor - Ratings and Ratios
Exchange: XETRA • Country: Germany • Currency: EUR • Type: Etf • ISIN: FR0010429068 • Global Emerging Markets Equity
LYM7: Emerging Markets, Stocks, Bonds, Equities
The Lyxor MSCI Emerging Markets UCITS ETF (Ticker: LYM7) is a Germany-domiciled exchange-traded fund designed to track the performance of the Morningstar Emerging Markets Target Market Exposure Net Total Return USD Index. This index provides exposure to large and mid-capitalization equities across emerging market economies. The ETF is listed on XETRA, offering European investors access to a diversified portfolio of emerging market stocks through a UCITS-compliant structure.
As of the latest data, the fund manages assets under management (AUM) of 799.13 million EUR, indicating its popularity among investors seeking exposure to emerging markets. The ETF category is classified under Global Emerging Markets Equity, reflecting its broad geographic focus. By tracking the Morningstar index, the fund aims to replicate the risk and return characteristics of the underlying emerging market equities, providing investors with a cost-efficient way to gain exposure to these high-growth regions.
Looking ahead, the outlook for emerging markets remains tied to macroeconomic trends such as inflation, interest rates, and global trade dynamics. As Aswath Damodaran would note, the valuations of emerging market equities will depend on their ability to navigate these factors while maintaining growth momentum. The ETFs performance will likely reflect broader emerging market trends, with potential headwinds from currency fluctuations and geopolitical risks. However, the long-term growth prospects of emerging markets, driven by urbanization and industrialization, continue to underpin the case for investment in this asset class.
Additional Sources for LYM7 ETF
LYM7 ETF Overview
Market Cap in USD | 866m |
Category | Global Emerging Markets Equity |
TER | 0.55% |
IPO / Inception | 2007-04-17 |
LYM7 ETF Ratings
Growth 5y | 41.3% |
Fundamental | - |
Dividend | 3.86% |
Rel. Strength Industry | -13.6 |
Analysts | - |
Fair Price Momentum | 11.81 EUR |
Fair Price DCF | - |
LYM7 Dividends
Dividend Yield 12m | 0.00% |
Yield on Cost 5y | % |
Annual Growth 5y | 0.00% |
Payout Consistency | 12.9% |
LYM7 Growth Ratios
Growth Correlation 3m | 25.5% |
Growth Correlation 12m | 80.3% |
Growth Correlation 5y | 21.2% |
CAGR 5y | 8.74% |
CAGR/Max DD 5y | 0.33 |
Sharpe Ratio 12m | 0.32 |
Alpha | 2.21 |
Beta | 0.64 |
Volatility | 17.83% |
Current Volume | 5.3k |
Average Volume 20d | 14.7k |
As of March 14, 2025, the stock is trading at EUR 12.72 with a total of 5,263 shares traded.
Over the past week, the price has changed by -1.36%, over one month by -4.19%, over three months by -2.58% and over the past year by +8.57%.
Partly, yes. Based on ValueRay Analyses, Multi Units France - Lyxor (XETRA:LYM7) is currently (March 2025) ok to buy, but has to be watched. It has a Growth Technical Rating of 41.33 and therefor an somewhat technical positive rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LYM7 as of March 2025 is 11.81. This means that LYM7 is currently overvalued and has a potential downside of -7.15%.
Multi Units France - Lyxor has no consensus analysts rating.
According to ValueRays Forecast Model, LYM7 Multi Units France - Lyxor will be worth about 13.1 in March 2026. The stock is currently trading at 12.72. This means that the stock has a potential upside of +2.91%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | - | - |
Analysts Target Price | - | - |
ValueRay Target Price | 13.1 | 2.9% |